GlaxoSmithKline’s investment income jumped to N310.3 million in the full year of 2022, a massive 231.7 percent from N93.54 million in the corresponding period of 2021.
Despite the increase in investment income, profit after tax for the period grew slightly by 5 percent to N692.05 million from N
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
Folake Balogun
Folake Balogun is a tech journalist covering Africa’s fast-growing digital economy with a strong focus on incisive analysis of startup trends, venture capital, and fintech innovation, while also exploring emerging technologies such as artificial intelligence and the future of connectivity by highlighting their economic and social impact.
